Navigation Links
High-Dose Chemo Provides Little Benefit to Breast Cancer Patients
Date:12/13/2007

Review of studies finds regimen popular in 1980s doesn't really lengthen life

THURSDAY, Dec. 13 (HealthDay News) -- High-dose chemotherapy has only a minimal effect on survival in breast cancer patients with node-positive disease, new research shows.

"It's pretty clearly established that [high-dose chemotherapy] is a false hope," said study author Donald Berry, head of the Division of Quantitative Sciences at the University of Texas M.D. Anderson Cancer Center in Houston. "There's a disease-free survival benefit but not much of a survival benefit. There may be a subset which would benefit, but we looked and couldn't find it."

The study, done in collaboration with the European Blood and Marrow Transplant Group, essentially sounds the death knell for this type of therapy.

"When you're doing a meta-analysis and combining large numbers of studies with different populations, and you're not able to get a really significant survival advantage, I think that the benefits of high-dose chemo are not there," added Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. "Outside of a clinical research trial, I do not recommend high-dose chemotherapy."

The findings are expected to be presented Thursday at the San Antonio Breast Cancer Symposium.

High-dose chemotherapy for breast cancer has a somewhat controversial history. The treatment is delivered in conjunction with an autologous (from the same person) bone marrow transplant, which rebuilds bone marrow damaged by the chemotherapy. The regimen was at one time favored for high-risk patients (those whose cancer has spread to at least four lymph nodes).

The rationale for the treatment came from successes in the 1960s and 1970s in treating certain leukemia patients with radiation and high-dose chemotherapy, along with bone marrow transplants.

By the late 1980s, the regimen was all the rage. An estimated 20,000 to 30,000 U.S. women have undergone high-dose chemotherapy with bone marrow transplants.

"Ten years ago, if a woman didn't get a bone marrow transplant, people were suing HMOS, because they said they were denying care," Brooks said. "The cases won."

Although progressively easier to tolerate, the therapy often caused nausea, vomiting, extreme weakness and infection. Some patients even died from the treatment.

Some small studies found that the treatment was beneficial for women with very high-risk cancer (at least 10 positive lymph nodes), but the trials were not randomized.

Later, randomized trials did not confirm the same benefit, and the treatment has largely fallen out of favor.

"But there were still some nagging questions," Berry said. "One was that maybe there was a subset who benefited."

Berry and his colleagues reviewed 15 randomized studies of high-dose chemotherapy conducted around the world between 1988 and 2002. Together, the trials involved more than 6,000 patients with a median follow-up of seven years.

There was a 13 percent decrease in the rate of breast cancer relapse in patients receiving high-dose chemotherapy. But that benefit did not extend survival. The decrease in mortality was only 6 percent, which was not statistically significant.

Increasing doses of chemotherapy do have some benefit for breast cancer patients, but it does reach a point of diminishing returns.

"Increasing the dose is good, but it reaches a plateau," confirmed Berry.

More information

The American Cancer Society has more on chemotherapy for breast cancer.



SOURCES: Donald Berry, Ph.D., professor and head, Division of Quantitative Sciences, University of Texas M.D. Anderson Cancer Center, Houston; Jay Brooks, M.D., chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La.; Dec. 13, 2007, presentation, San Antonio Breast Cancer Symposium, Texas; Sept. 6, 2007, New England Journal of Medicine


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. High-dose chemo and stem cell transplant shows little or no survival benefit for breast cancer
2. Chemotherapy may be culprit for fatigue in breast cancer survivors
3. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
4. To evade chemotherapy, some cancer cells mimic stem cells
5. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
6. PET scans can accurately detect a breast tumors response to chemotherapy
7. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
8. New Software Program Helps Breast Cancer Survivors and Patients Fight Chemofog
9. Medicare modernization act did not change chemotherapy as feared
10. HER-2 status predicts success of chemotherapy in breast cancer treatment, study finds
11. Cancer conflict with chemotherapy treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
High-Dose Chemo Provides Little Benefit to Breast Cancer Patients
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
(Date:6/23/2016)... Research and Markets has announced ... Analysis (United States, China, Japan, Brazil, United Kingdom, Germany, ... offering. Surgical Procedure ... planners, provides surgical procedure volume data in a geographic ... in-depth analysis of growth drivers and inhibitors, including world ...
Breaking Medicine Technology: